Company Profiles

driven by the PitchBook Platform

Oligomerix

Description

Developer of novel therapeutics for Alzheimer's disease and related neurodegenerative disorders. The company's novel therapeutics helps to discover and develop the most effective disease modifying therapeutics to meet the major global unmet medical need for Alzheimer's and related neurodegenerative diseases by targeting tau oligomers, enabling technologies for large pharmaceutical licensees, partners and acquirers to play a major role in successfully intervening in this costly, debilitating disease.

2006

Founded

PRIVATE

Status

1-10

Employees

Grant

Latest Deal Type

$1.5M

Latest Deal Amount

$5.91M

Total Amount Raised

Description

Developer of novel therapeutics for Alzheimer's disease and related neurodegenerative disorders. The company's novel therapeutics helps to discover and develop the most effective disease modifying therapeutics to meet the major global unmet medical need for Alzheimer's and related neurodegenerative diseases by targeting tau oligomers, enabling technologies for large pharmaceutical licensees, partners and acquirers to play a major role in successfully intervening in this costly, debilitating disease.

Website:

www.oligomerix.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology
Other Pharmaceuticals and Biotechnology

Primary Office

3960 Broadway Suite 340D New York, NY 10032United States +1 (212) 568-0365
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Oligomerix's full profile, request a free trial.

Oligomerix Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Oligomerix Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Oligomerix Investors (5)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Durand Venture AssociatesVenture CapitalMinority000 0000000 0000
Individual InvestorAngel (individual)Minority000 0000000 0000
National Institute On AgingOther000 0000000 0000
National Institutes of HealthGovernment000 0000000 0000
Wheatley PartnersPE/BuyoutMinority000 0000000 0000
Durand Venture Associates Venture Capital
Individual Investor Angel (individual)
National Institute On Aging Other
National Institutes of Health Government
Wheatley Partners PE/Buyout

Oligomerix Executive Team (3)

NameTitleBoard
Seat
Contact
Info
James Moe Ph.DCo-Founder, President, Director, Principal Investigator, Board Member & Chief Executive Officer
Jack PasiniBoard Member, Director & Chief Commercial Officer
Eliot DavidowitzCo-Founder & Chief Scientist
James Moe Ph.D Co-Founder, President, Director, Principal Investigator, Board Member & Chief Executive Officer
Jack Pasini Board Member, Director & Chief Commercial Officer
Eliot Davidowitz Co-Founder & Chief Scientist

Oligomerix Board Members (6)

NameRepresentingRoleSinceContact
Info
David Dantzker MDWheatley PartnersGeneral Partner000 0000
Douglas DurandDurand Venture AssociatesFounder and Managing Director000 0000
Jack PasiniOligomerixBoard Member, Director & Chief Commercial Officer000 0000
James Moe Ph.DOligomerixCo-Founder, President, Director, Principal Investigator, Board Member & Chief Executive Officer000 0000
Jeffrey BluesteinSelfBoard Member000 0000
David Dantzker MD General Partner Wheatley Partners
Douglas Durand Founder and Managing Director Durand Venture Associates
Jack Pasini Board Member, Director & Chief Commercial Officer Oligomerix
James Moe Ph.D Co-Founder, President, Director, Principal Investigator, Board Member & Chief Executive Officer Oligomerix
Jeffrey Bluestein Board Member Self
Request full access to PitchBook